Expertise in
5
conditions

Dr. Kimberly A. Mcgregor

Oncology
Quest Diagnostics
750 Wellington Ave, 
Grand Junction, CO 
Offers Telehealth
Expertise in
5
conditions
Quest Diagnostics
750 Wellington Ave, 
Grand Junction, CO 

Overview

Kimberly Mcgregor is an Oncologist practicing medicine in Grand Junction, Colorado.

Dr. Mcgregor is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Angiosarcoma, and Paget Disease of the Breast.

She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 5 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CO

Hospital Affiliations

Intermountain Health St. Mary's Regional Hospital
Trinity Hospitals
Moab Regional Hospital
Grand River Hospital District
Valley View Hospital Association

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Quest Diagnostics
750 Wellington Ave, Grand Junction, CO 81501

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

2 Total Publications

CGE25-111: Enhancing Oncology Treatment Personalization through Plasma Proteomics and Machine Learning.
CGE25-111: Enhancing Oncology Treatment Personalization through Plasma Proteomics and Machine Learning.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
Similar Doctors
Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Quest Diagnostics

750 Wellington Ave, 
Grand Junction, CO 
 (0.1 miles away)
970-298-7500
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bradley Corr is an Oncologist practicing medicine in Grand Junction, Colorado. He has been practicing medicine for over 17 years. Dr. Corr is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Tissue Biopsy. Dr. Corr is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Grand Valley Gynecologic Oncology

688 23 1/2 Rd Ste 201, 
Grand Junction, CO 
 (11.5 miles away)
970-644-3821
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Glenn Bigsby is an Oncologist practicing medicine in Grand Junction, Colorado. Dr. Bigsby is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Malignant Mixed Mullerian Tumor, Vulvar Cancer, Testicular Yolk Sac Tumor, and Salpingo-Oophorectomy. Dr. Bigsby is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Grand Valley Laboratory

603 28 1/4 Rd, 
Grand Junction, CO 
 (1.4 miles away)
970-644-3190
Languages Spoken:
English
See accepted insurances

Ruth Higdon is an Oncologist practicing medicine in Grand Junction, Colorado. Dr. Higdon is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Vulvar Cancer, Vaginal Cancer, Melanoma, Malignant Mixed Mullerian Tumor, and Colonoscopy.

Frequently Asked Questions about Dr. Kimberly A. Mcgregor

How do I make an appointment with Dr. Kimberly A. Mcgregor?

You can book an appointment with Dr. Kimberly A. Mcgregor by calling their office at 970-298-7500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kimberly A. Mcgregor a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kimberly A. Mcgregor is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kimberly A. Mcgregor specialize in?

While Dr. Kimberly A. Mcgregor is a Oncology, they have specific expertise in Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Kimberly A. Mcgregor participate in research or clinical trials?

Yes. Dr. Kimberly A. Mcgregor has published 2 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Kimberly A. Mcgregor's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kimberly A. Mcgregor accept my insurance?

Dr. Kimberly A. Mcgregor accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 970-298-7500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcgregor's expertise for a condition
ConditionClose
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile